Related Experiment Video
Updated: Jun 26, 2026
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
Pediatric low-grade gliomas and the need for new options for therapy: Why and how?
Ibrahim Qaddoumi1, Iyad Sultan, Alberto Broniscer
1Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Ibrahim.Qaddoumi@stjude.org
Abstract:
Pediatric low-grade gliomas are the most common tumors of the central nervous system in children, accounting for almost 50% of all childhood brain tumors. They are a heterogeneous group of tumors with different histologic subtypes. Most treatment studies address low-grade gliomas as a single entity, depriving us of histology-specific treatment outcomes. This is mostly due to a lack of understanding of tumor biology at the molecular level. Pediatric low-grade gliomas are not benign, and most incompletely resected tumors will progress and negatively affect quality of life. The advancements made in understanding sporadic pilocytic astrocytoma and neurofibromatosis 1-associated pilocytic astrocytoma in particular have paved the way for potential targeted therapy and biological stratification. Such progress in pilocytic astrocytoma needs to be consolidated and expanded to other histologic varieties of pediatric low-grade gliomas.
Insights
Pediatric low-grade gliomas, common childhood brain tumors, require histology-specific treatments. Understanding tumor biology advances targeted therapies for better outcomes.
Area of Science:
- Pediatric neuro-oncology
- Molecular biology of brain tumors
- Cancer genomics
Background:
- Pediatric low-grade gliomas are the most frequent pediatric central nervous system tumors, comprising 50% of childhood brain tumors.
- Current treatment studies often group diverse low-grade gliomas, hindering histology-specific outcome analysis.
- A deeper understanding of tumor biology at the molecular level is crucial for effective treatment strategies.
Purpose of the Study:
- To highlight the need for histology-specific treatment outcomes in pediatric low-grade gliomas.
- To emphasize the importance of molecular understanding for targeted therapies.
- To advocate for expanding research beyond pilocytic astrocytoma to other low-grade glioma subtypes.
Main Methods:
- Review of current literature on pediatric low-grade gliomas.
- Analysis of molecular advancements in pilocytic astrocytoma.
- Identification of knowledge gaps in other histologic subtypes.
Main Results:
- Pediatric low-grade gliomas are a heterogeneous group, not uniformly benign.
- Incompletely resected tumors often progress, impacting quality of life.
- Progress in understanding pilocytic astrocytoma biology offers a model for targeted therapy development.
Conclusions:
- Advancements in understanding pilocytic astrocytoma biology, including sporadic and NF1-associated types, are paving the way for targeted therapies.
- Consolidating and expanding this molecular understanding to other pediatric low-grade glioma histologic subtypes is essential.
- Histology-specific research is critical for improving treatment efficacy and patient outcomes in pediatric low-grade gliomas.
